stockrow
Saturday 7 November 2026
Export GLUE’s income statement to Excel — free account
Monte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024.
- Revenue
- +325.8%
- EPS
- +109.1%
- Free cash flow
- −142.6%
Quarter to September 2026, against a year earlier
10.49
0.24
+2.34%
Follow GLUE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 76 | 124 | 70 | +63.5% | 73 | 65 | 107 | (4.8%) | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | — | — | — | (8) | (36) | (74) | (109) | (135) | (70) | (40) | (130) | +31.3% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (92.74) | (32.12) | (184.77) | (32.1) pt | ||||||
| Net income | — | 0 | — | (8) | (36) | (74) | (109) | (135) | (73) | (39) | (131) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.02 | 1.49 | 0.69 | n/m | |||||
| Earnings | — | — | — | (0.18) | (23.65) | (2.96) | (2.30) | (2.63) | (0.98) | (0.46) | (1.40) | +16.9% | ||||||
| Cash flow | — | — | — | (0.14) | (15.20) | (2.37) | (1.96) | (0.85) | 0.57 | (0.27) | (1.63) | +11.8% | ||||||
| Capex | — | — | — | 0.00 | (2.23) | (0.39) | (0.27) | (0.37) | (0.05) | (0.06) | (0.09) | n/m | ||||||
| Free cash flow | — | — | — | (0.14) | (17.43) | (2.76) | (2.23) | (1.22) | 0.51 | (0.33) | (1.71) | +15.4% | ||||||
| Book value | — | — | — | (0.28) | (32.12) | 13.90 | 5.75 | 3.49 | 3.02 | 2.81 | 4.87 | n/m | ||||||
| Shares, m | — | — | — | 44 | 2 | 25 | 47 | 51 | 74 | 83 | 97 | +11.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 6.78 | 10.53 | 15.18 | 8.7 | ||||||
| P/B | — | — | — | — | — | — | — | — | 2.30 | 5.59 | 2.15 | 3.9 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 1.86 | 7.48 | 6.97 | 4.7 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | 3.70 | (33.66) | (2.81) | (15.0) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (6) | (23) | (59) | (92) | (44) | 42 | (23) | (165) | +24.3% | |||||
| Capex | — | — | — | (1) | (3) | (10) | (13) | (19) | (4) | (5) | (9) | +22.6% | ||||||
| Free cash flow | — | — | — | (6) | (26) | (69) | (105) | (63) | 38 | (27) | (174) | +28.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 5 | 14 | 332 | 250 | 190 | 220 | 329 | 578 | +98.0% | |||||
| Net debt | — | — | — | 10 | (42) | (346) | (264) | (232) | (372) | (377) | (578) | n/m | ||||||
| Shareholders’ equity | — | — | — | (12) | (49) | 348 | 271 | 179 | 223 | 233 | 496 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (139.53) | (118.66) | (35.58) | (30.62) | (41.90) | (19.58) | (8.71) | (22.63) | +130.8 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (3,154.52) | (920.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 25.43 | 117.88 | (49.51) | (35.06) | (60.07) | (36.15) | (16.94) | (35.30) | (42.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 75 | 93 | 123 | 133 | 134 | 150 | — | +14.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.82 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Monte Rosa Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences, Inc. | $896.7M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $867.9M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LTGO Latigo Biotherapeutics Inc | $862.6M | — | — | — | n/m | — | — | 0.00% | Compare |
| ANRO Alto Neuroscience, Inc. | $858.2M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $853.9M | 2.4× | 16.4× | +16.45% (above 0%: growing) | −54.84% (below 0%: shrinking) | +43.90% (above 0%: growing) | 86.67% | 21.15% | Compare |
| Median of peers | $869.3M | — | — | +16.45% | — | −23.41% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
6.40%
Entities affiliated with New Enterprise Associates
9.10%
Entities affiliated with Dimension Capital
7.70%
T. Rowe Price Associates, Inc.
5.50%
Entities affiliated with TCG Crossover
5.30%
Entities affiliated with Baker Bros
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement